Welcome to our dedicated page for Nasus Pharma Ltd. SEC filings (Ticker: NSRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nasus Pharma Ltd. (NSRX) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on the NYSE American. Nasus Pharma files reports with the U.S. Securities and Exchange Commission that include current information on its clinical programs, financial condition, governance, and material agreements.
Nasus Pharma submits current reports on Form 6-K, which have covered topics such as condensed unaudited interim financial statements and management’s discussion and analysis for specified periods, leadership appointments, clinical trial milestones, and collaboration agreements. For example, Form 6-K reports have described the appointment of an Executive Vice President and Chief Financial Officer, the initiation of a Phase 2 clinical study of NS002 with first participant dosed, and expanded agreements with Aptar France S.A.S. and AptarGroup, Inc. to support the intranasal epinephrine program.
Filings also document capital markets events, including the registration and completion of Nasus Pharma’s initial public offering on Form F-1 and subsequent updates on the partial exercise of the underwriters’ over-allotment option. These disclosures outline the company’s stated use of proceeds, such as funding further development of its intranasal epinephrine program and general corporate purposes, and provide detail on underwriting arrangements.
As a foreign private issuer, Nasus Pharma is required to file an annual report on Form 20-F, and it supplements this with periodic Form 6-K submissions when it releases press statements or corporate presentations that are material to investors. Some 6-K filings incorporate press releases, such as the CEO’s letter to shareholders or news of regulatory clearances, directly as exhibits.
On this page, users can review Nasus Pharma’s SEC filings as they are made available through the EDGAR system. Stock Titan enhances access by pairing filings with AI-powered summaries that help explain key sections, highlight clinical and financial themes, and make lengthy documents such as financial statements and management analyses easier to understand. Investors can quickly identify filings related to clinical progress of NS002, leadership and governance changes, capital raising activities, and significant collaboration agreements.
Nasus Pharma Ltd. submitted a report stating that it has made an updated corporate presentation available on its website in February 2026. The presentation, dated February 2026, is attached as Exhibit 99.1. The company clarifies that this material is not a prospectus or offering document and should not be treated as an offer to sell or buy any securities, or as the basis for any related contract or commitment.
Nasus Pharma closed a private placement of ordinary shares and warrants, raising aggregate gross proceeds of approximately $15.0 million before fees and expenses. The financing is intended to support development of NS002, the company’s powder-based intranasal epinephrine product for anaphylaxis, and other pipeline programs.
The company sold 2,695,425 ordinary shares and accompanying warrants to purchase up to 2,695,425 additional shares at a combined purchase price of $5.565 per share and warrant, a premium to the last NYSE American closing price before signing. The warrants have an exercise price of $6.53 per share, are immediately exercisable, and will expire on the earlier of two years from issuance and 30 trading days after Nasus announces top-line results from its NS002 pivotal study.
Nasus plans to use the net proceeds, together with existing cash and investments, to advance NS002 through pivotal clinical development and toward a New Drug Application, begin first-in-human studies for other intranasal powder products, and for working capital and general corporate purposes.
Nasus Pharma entered into a definitive agreement for a private placement with institutional and accredited investors, raising approximately $15.0 million in gross proceeds. Investors will buy 2,695,425 ordinary shares plus accompanying warrants to purchase up to 2,695,425 additional shares at a combined price of $5.565 per share and warrant.
The warrants have an exercise price of $6.53 per share, are immediately exercisable, and expire the earlier of two years from issuance or 30 trading days after announcement of top-line results from the NS002 pivotal study. Nasus plans to use the net proceeds to advance NS002 for anaphylaxis, start first-in-human studies for other pipeline products, and for working capital and general corporate purposes. The offering is expected to close on or about February 12, 2026, with placement agents receiving a 6.0% cash fee on gross proceeds and $55,000 in expense reimbursement.
Nasus Pharma Ltd. has called a Special General Meeting of shareholders for March 5, 2026, in Tel Aviv. Shareholders of record on February 9, 2026 will be entitled to vote.
On the agenda are proposals to increase authorized share capital, amend the articles of association, approve equity-based compensation for non-executive directors and the Chief Financial Officer, approve a milestone-based grant for the Chief Executive Officer, and approve a U.S. sub-plan to the company’s 2019 Incentive Option Plan.
Nasus Pharma Ltd. reported positive interim results from its Phase 2 study of NS002, an intranasal epinephrine powder being developed to treat anaphylaxis. In 25 evaluated participants, NS002 achieved a higher mean peak epinephrine plasma concentration of 655 pg/ml versus 548 pg/ml for EpiPen® and reached peak levels in 10.8 minutes compared with 15 minutes for EpiPen®.
Notably, 91% of participants given NS002 reached the 100 pg/ml epinephrine threshold at 5 minutes, versus 67% with EpiPen®, and early exposure over the first 10 minutes was higher with NS002 (AUC 55 h*pg/ml vs. 32 h*pg/ml). NS002 was well-tolerated in all 50 subjects who completed all treatment arms, with no serious adverse events and mostly mild, local effects, and its effects on blood pressure and pulse were comparable to EpiPen®. Nasus expects full Phase 2 results by the end of the first quarter of 2026 and plans to start a pivotal study in the fourth quarter of 2026.
Nasus Pharma Ltd. furnished a Form 6-K for December 2025 that makes available its condensed unaudited interim financial statements and related management discussion. These documents cover the six-month period ended June 30, 2025 and are provided as Exhibits 99.1 and 99.2 for investors’ review.
Nasus Pharma Ltd. furnished a Form 6-K to provide investors with a press release titled “Nasus Pharma CEO Issues 2025 Letter to Shareholders.” The press release, dated December 22, 2025, is attached as Exhibit 99.1 and contains the CEO’s 2025 shareholder letter.
Nasus Pharma Ltd. (NSRX) announced that it has appointed Eyal Rubin as its new Chief Financial Officer and Executive Vice President, effective November 19, 2025. The company entered into an Employment Agreement with him on the same date and expects to provide its standard indemnification agreement, similar to those for other directors and executive officers. The company states that there are no related party transactions involving Mr. Rubin that require disclosure. Mr. Rubin brings extensive experience from prior CFO roles at Protalix BioTherapeutics and BrainStorm Cell Therapeutics, and treasury leadership roles at Teva Pharmaceutical Industries. Nasus Pharma also issued a press release on November 20, 2025 announcing his appointment.
Nasus Pharma Ltd. reported that it has begun a Phase 2 clinical study of its product candidate NS002, with the first participant already dosed. This step marks a move into a more advanced stage of human testing, where the company will further evaluate NS002’s performance and safety in patients. The update was provided through a press release dated November 18, 2025, which is attached to this report as an exhibit.
Nasus Pharma Ltd (NSRX): Schedule 13G filed — Dr. Ronnie Hershman reported beneficial ownership of 1,383,512 ordinary shares, representing 15.3% of the class. The filing attributes 891,187 shares to Hershman Holdings LLC (managed by Dr. Hershman) with sole voting and dispositive power; 429,307 shares are held by Phoenix Solutions Ltd., where he may be deemed to share voting and investment power; and 63,018 shares are issuable upon exercise of options exercisable within 60 days.
For Hershman Holdings LLC alone, the filing shows 891,187 shares (9.9%) with sole voting and dispositive power. The percentages are based on 9,014,105 ordinary shares outstanding as of September 30, 2025.